RICHMOND, Calif., April 10, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, this flagship event features 16 of the regenerative medicine field's leading small- and mid-cap companies.
The following are specific details regarding Sangamo BioSciences' presentation at the conference:
ARM's Regen Med Investor Day
April 17, 2013
Harmonie Club, 4 East 60th Street, New York, NY 10022
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on both the Sangamo and ARM websites after the event.
The event also includes disease indication-focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote-style talks by Jeff Jonas, President of Shire Regenerative Medicine and Kieran Murphy, President and CEO, GE Healthcare Life Sciences.
Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at firstname.lastname@example.org. Please visit http://alliancerm.org/event/regen-med-investor-day for more information.
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.